Connected profiles1
Exact peptide identities attached to retained registry observations carrying this condition label.
Coverage-gated living condition brief
Prostate Cancer peptide evidence brief
A cited Prostate Cancer peptide evidence brief across 18 exact-label ClinicalTrials.gov records, 1 connected profile, and 9 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
Registry records
18 selected records.
Connected peptides
1 profiles.
Registry update years
2010–2026 in selected records.
Direct collection answer · published August 17, 2026
What peptide evidence does PeptideScanner carry for Prostate Cancer?
PeptideScanner’s selected collection contains 18 retained ClinicalTrials.gov records carrying the exact condition label “Prostate Cancer,” connected to 1 peptide profile across 9 registry-update years.
That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Prostate Cancer, and it is not a safety or efficacy assessment.
Indication intelligence
Selected evidence landscape
Trial phases3
Phase labels copied from the retained ClinicalTrials.gov versions.
Phase 2 (13)Phase 1 (6)Phase 3 (3)
Registry statuses3
Overall statuses at each retained observation, not necessarily current today.
Completed (14)Recruiting (2)Active, not recruiting (2)
Across the connected peptide profiles, PeptideScanner also carries 46 selected PubMed records and 24 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Prostate Cancer unless their own cited source says so.
Related profile context
Literature connected through these peptide profiles
This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Prostate Cancer.
Leuprolide · source record 2026-06-16
Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances: Characterization of Degradation Products With LC-MS.
PubMed lists PMID 42299119 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2026-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Leuprolide · source record 2013-11-21
Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
PubMed lists PMID 16312848 in Journal of chemotherapy (Florence, Italy) as Journal Article, with publication-date metadata of 1989-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Leuprolide · source record 2013-11-21
Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations.
PubMed lists PMID 15685898 in The Netherlands journal of medicine as Case Reports, Journal Article, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Leuprolide · source record 2013-11-21
The role of leuprolide acetate therapy in triggering auto-immune thyroiditis.
PubMed lists PMID 15689930 in The Journal of pediatrics as Comment, Letter, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Leuprolide · source record 2013-11-21
LC determination of leuprolide component amino acids in injectable solution by phanquinone pre-column derivatization labelling procedure.
PubMed lists PMID 15862697 in Journal of pharmaceutical and biomedical analysis as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2005-04-29 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Leuprolide · source record 2013-11-21
Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
PubMed lists PMID 16111462 in Expert review of anticancer therapy as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
Record added
ClinicalTrials.gov record NCT07455903
PeptideScanner retained ClinicalTrials.gov record NCT07455903 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was leuprolide.
- PeptideScanner change date
- August 14, 2026
- Cited source date
- August 6, 2026
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT00002881
PeptideScanner retained ClinicalTrials.gov record NCT00002881 at 2026-07-30T22:25:23.114Z. Its registry update date was 2010-11-09, and PeptideScanner's reviewed identity mapping was leuprolide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- November 9, 2010
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT00003124
PeptideScanner retained ClinicalTrials.gov record NCT00003124 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-01-06, and PeptideScanner's reviewed identity mapping was leuprolide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- January 6, 2014
- Evidence lane
- Clinical trials
Exact-record source chronology
Prostate Cancer registry timeline
Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.
2026
4 recordsLeuprolide · 2026-08-06
ClinicalTrials.gov record NCT07455903
Recruiting at the retained observation.
Open cited registry record →Leuprolide · 2026-07-30
ClinicalTrials.gov record NCT05765500
Recruiting at the retained observation.
Open cited registry record →Leuprolide · 2026-07-10
ClinicalTrials.gov record NCT05498272
Active, not recruiting at the retained observation.
Open cited registry record →Leuprolide · 2026-07-09
ClinicalTrials.gov record NCT02319837
Active, not recruiting at the retained observation.
Open cited registry record →2019
1 recordLeuprolide · 2019-07-24
ClinicalTrials.gov record NCT00669162
Completed at the retained observation.
Open cited registry record →2017
3 recordsLeuprolide · 2017-06-01
ClinicalTrials.gov record NCT00225420
Completed at the retained observation.
Open cited registry record →Leuprolide · 2017-05-30
ClinicalTrials.gov record NCT01431391
Completed at the retained observation.
Open cited registry record →Leuprolide · 2017-05-24
ClinicalTrials.gov record NCT02107391
Completed at the retained observation.
Open cited registry record →2016
3 recordsLeuprolide · 2016-12-13
ClinicalTrials.gov record NCT00928434
Completed at the retained observation.
Open cited registry record →Leuprolide · 2016-09-19
ClinicalTrials.gov record NCT01076335
Completed at the retained observation.
Open cited registry record →Leuprolide · 2016-05-25
ClinicalTrials.gov record NCT00943956
Completed at the retained observation.
Open cited registry record →2015
2 recordsLeuprolide · 2015-04-28
ClinicalTrials.gov record NCT00500110
Completed at the retained observation.
Open cited registry record →Leuprolide · 2015-01-29
ClinicalTrials.gov record NCT00631527
Completed at the retained observation.
Open cited registry record →2014
2 recordsLeuprolide · 2014-05-15
ClinicalTrials.gov record NCT01088529
Completed at the retained observation.
Open cited registry record →Leuprolide · 2014-01-06
ClinicalTrials.gov record NCT00003124
Completed at the retained observation.
Open cited registry record →2013
1 recordLeuprolide · 2013-06-24
ClinicalTrials.gov record NCT00003394
Completed at the retained observation.
Open cited registry record →2012
1 recordLeuprolide · 2012-03-19
ClinicalTrials.gov record NCT00653757
Completed at the retained observation.
Open cited registry record →2010
1 recordLeuprolide · 2010-11-09
ClinicalTrials.gov record NCT00002881
Completed at the retained observation.
Open cited registry record →- Condition matching is limited to exact labels on retained ClinicalTrials.gov v3 observations; PeptideScanner does not merge related diagnoses or synonyms.
- Coverage is selective and historical, not a complete or continuously current account of the registry or PubMed.
- The brief does not synthesize study outcomes, compare interventions, or make safety, efficacy, diagnosis, or treatment claims.